Freedom Broker Lifts Amgen Price Target to $470 From $450
Freedom Broker raised its Amgen price target to $470 per share from $450, according to a Dow Jones Newswires report based on Benzinga ratings data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Freedom Broker increased its target price for Amgen shares to $470 from $450. Dow Jones Newswires reported the change, citing Benzinga's ratings data.
The original report contains only the fact of the change, with no details on the reasoning behind it.
why it matters
A higher target price means the analyst sees the company's shares as worth more than before. Single-broker revisions like this tend to affect sentiment around a stock, but they carry little weight for the broader market.
tags
instruments
sources
- Amgen Price Target Raised to $470.00/Share From $450.00 by Freedom Broker — Dow Jones Newswires, 7 November 2026 at 00:02 UTC
- Allison Transmission Price Target Raised to $147.00/Share From $144.00 by Freedom Broker — Dow Jones Newswires, 7 November 2026 at 00:21 UTC
- ExxonMobil Holdings Price Target Raised to $162.00/Share From $142.00 by Freedom Broker — Dow Jones Newswires, 7 November 2026 at 00:23 UTC
- Pfizer Price Target Raised to $34.00/Share From $33.00 by Freedom Broker — Dow Jones Newswires, 7 November 2026 at 00:22 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗